SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
103 hedge funds and large institutions have $48.4M invested in SANGAMO THERAPEUTICS INC in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 40 closing their positions.
56% more capital invested
Capital invested by funds: $31.1M → $48.4M (+$17.3M)
15.02% less ownership
Funds ownership: 41.88% → 26.86% (-15%)
20% less funds holding
Funds holding: 129 → 103 (-26)
36% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 36
63% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 40
66% less call options, than puts
Call options by funds: $525K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.3M |
| 2 |
Renaissance Technologies
New York
|
+$532K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$199K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$180K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.04M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.69M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.63M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.08M |
| 5 |
Goldman Sachs
New York
|
-$927K |
SGMO Hedge Fund Activity: Q3 2024 in Review
103 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2024, worth a combined $48.4M — up 56% from $31.1M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of SGMO and 15 opened new positions — a net loss of 25 holders — while 36 trimmed existing stakes and 23 added.
The largest buyer was Marshall Wace, adding an estimated $1.3M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.04M sold.
- 103 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2024, down from 129 in Q2 2024.
- Funds reported $48.4M of SANGAMO THERAPEUTICS INC stock for Q3 2024, up 56% quarter-over-quarter.
- 15 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2024 and 40 closed out, a net change of -25 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2024 was Marshall Wace, an estimated $1.3M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2024 was Armistice Capital, an estimated $5.04M sold.
Based on aggregated 13F filings for Q3 2024.